Trial · NCT01637584
Neurobiology of Sleep and Sleep Treatment Response in Returning Veterans
NCT01637584, Not applicable, Completed, University of Pittsburgh; results first posted 2017-04-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Neurobiology of Sleep and Sleep Treatment Response in Returning Veterans. Trials, record NCT01637584. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01637584
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Neurobiology of Sleep and Sleep Treatment Response in Returning Veterans
- NCT number
- NCT01637584
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 40 participants, actual
- Lead sponsor
- University of Pittsburgh
- Conditions
- Non PTSD, PTSD
- Interventions
- Prazosin, Placebo
- First posted
- 2012-07-11
- Last updated
- 2017-05-23
- Results first posted
- 2017-04-17
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Whole Brain Relative Regional Cerebral Metabolic Rate of Glucose | Baseline and post-intervention at 8-10 weeks | The reported Z value reflect the magnitude of the state difference (Wake vs. Non-REM or Wake vs. REM) within the prazosin group pre-to-post treatment, and after using a mask to adjust for the spurious effects of the passage of time. |
| Secondary | Pittsburgh Sleep Quality Index (PSQI): | Baseline and post-treatment at 8-10 weeks | Self-report sleep quality measure. Scores range from 0 to 21, with higher scores reflecting poorer sleep quality. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Whole Brain Relative Regional Cerebral Metabolic Rate of Glucose | Baseline and post-intervention at 8-10 weeks | 9 of the 20 participants who were randomized to prazosin and 13 of the participants randomized to placebo provided scans pre- and post-treatment that were of sufficiency quality to be included in the final analyses. | Z values | NUMBER |
| SECONDARY | Pittsburgh Sleep Quality Index (PSQI): | Baseline and post-treatment at 8-10 weeks | 9 of the 20 participants who were randomized to prazosin and 13 of the participants randomized to prazosin provided scans pre- and post-treatment that were of sufficiency quality to be included in the final analyses. | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group10
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Whole Brain Relative Regional Cerebral Metabolic Rate of Glucose | Prazosin -Placebo | Pre-to-Post Treatment (Wakefulness > NREM) | 3.78 | Z values | |
| Whole Brain Relative Regional Cerebral Metabolic Rate of Glucose | Prazosin -Placebo | Pre-to-Post Treatment (Wakefulness < NREM) | 3.76 | Z values | |
| Whole Brain Relative Regional Cerebral Metabolic Rate of Glucose | Prazosin -Placebo | Pre-to-Post Treatment (Wakefulness > REM) | 3.52 | Z values | |
| Whole Brain Relative Regional Cerebral Metabolic Rate of Glucose | Prazosin -Placebo | Pre-to-Post Treatment (Wakefulness < REM) | 3.36 | Z values | |
| Whole Brain Relative Regional Cerebral Metabolic Rate of Glucose | Prazosin -Placebo | Within-state time-dependent decrease in rCMRglc | 4.12 | Z values | |
| Whole Brain Relative Regional Cerebral Metabolic Rate of Glucose | Prazosin -Placebo | Within-state time-dependent increase in rCMRglc | 3.89 | Z values | |
| Pittsburgh Sleep Quality Index (PSQI): | Prazosin | PSQI: Baseline | 9.25 | Standard Deviation 2.64 | units on a scale |
| Pittsburgh Sleep Quality Index (PSQI): | Placebo | PSQI: Baseline | 8.08 | Standard Deviation 2.72 | units on a scale |
| Pittsburgh Sleep Quality Index (PSQI): | Prazosin | PSQI: Post | 6.71 | Standard Deviation 4.31 | units on a scale |
| Pittsburgh Sleep Quality Index (PSQI): | Placebo | PSQI: Post | 6.54 | Standard Deviation 2.57 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Prazosin | 20 | |
| Overall Study | STARTED | Placebo | 20 | |
| Overall Study | COMPLETED | Prazosin | 19 | |
| Overall Study | COMPLETED | Placebo | 17 | |
| Overall Study | NOT COMPLETED | Prazosin | 1 | |
| Overall Study | NOT COMPLETED | Placebo | 3 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Prazosin | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Prazosin | 0 | 20 |
| Total, other adverse events | Placebo | 0 | 20 |
| Total, serious adverse events | Prazosin | 0 | 20 |
| Total, serious adverse events | Placebo | 0 | 20 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 24893322 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Prazosin vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01637584
GET https://conductscience.org/api/trials/v1/NCT01637584/registered